Executive Summary

Standardised Pharmaceutical Grade CBD (Cannabidiol)

Cannabidiol (CBD) is a non-addictive, non-psychoactive agent, binding to human cannabinoid receptors. Its potential medical and health effects are now the target of extensive research worldwide.
Further research will only increase product demand as the knowledge base of efficacies grows.

Cannabidiol (CBD) is the second most prevalent cannabinoid of over one hundred (100) phytochemical cannabinoids identified in hemp plants.

Consumer interest in CBD is increasing exponentially. The extensive range of current CBD products in the market are of widely varying qualities. Its growth is only limited by the markets’ ability to supply a legitimate standardised product.

All indicators dictate there is a multi-billion-dollar market for standardised pharmaceutical grade CBD.

Current CBD production is predominantly agricultural, a costly and time-consuming process. The challenge was to develop a Standardised Pharmaceutical Grade CBD.

BIOPHARM LIMITED now has the patent to produce standardised pharmaceutical grade CBD.